| Outcome Measures: |
Primary: Effect of Renal Function on Maximum Plasma Concentration of TA-7284, For 72 hours after each administration|Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284, For 72 hours after each administration|Effect of Renal Function on Urinary Glucose Excretion of TA-7284, For 24 hours after each administration|Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284, The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC - urinary glucose excretion) on the preceding day and on the day of administration., For 24 hours after each administration | Secondary: Adverse Events, Incidence and severity of AEs, Upto approximately 14 days after last administration|12-lead Electrocardiogram (ECG), Change from baseline in ECG parameters, For 72 hours after each administration|Vital Signs, Change from baseline in Vital signs (BP, PR and BT), For 72 hours after each administration|Clinical Laboratory Tests, Change from baseline in Clinical laboratory tests, For 72 hours after each administration
|
